Halozyme Expands Oncology Reach with GSK ADC Delivery Deal

Event summary

  • Halozyme licenses ENHANZE® technology to GSK for subcutaneous ADC delivery in oncology.
  • First collaboration for ADC targets, expanding Halozyme's addressable market.
  • GSK to make upfront payment plus potential milestone payments and royalties.
  • First clinical trial expected to initiate in 2026.
  • ENHANZE® has been licensed to over 15 leading pharmaceutical and biotechnology companies.

The big picture

This deal positions Halozyme at the forefront of the rapidly growing ADC therapeutic class, reinforcing its role as a key player in drug delivery technology. The collaboration with GSK underscores the industry's recognition of ENHANZE® as a gold standard for subcutaneous delivery, potentially expanding Halozyme's addressable market and reinforcing its high-margin royalty revenue model.

What we're watching

Market Expansion
How the inclusion of ADC targets will affect Halozyme's market reach and royalty revenue growth.
Clinical Progress
The pace at which GSK advances the first clinical program under this collaboration.
Partnership Dynamics
Whether Halozyme can sustain its high-margin royalty business with additional pharmaceutical partnerships.

Related topics

Oncology